Impact of different antibiotic regimens in the treatment of. Request pdf combination therapy for carbapenemresistant gramnegative bacteria the emergence of resistant to carbapenems. This metaanalysis aims to compare intravenous colistin monotherapy and colistinbased combination therapy against carbapenemresistant gramnegative bacteria gnb infections. The aim of this study was to analyze the clinical effectiveness of cct over monotherapy in patients with crgnb. In this context, along with strong preclinical evidence of benefit in combining antimicrobials against cr gnb, the clinical use of combination therapy has been. Combination therapy was the preferred treatment strategy for infections caused by carbapenem resistant gram negative bacteria among hospital representatives. Carbapenem resistant acinetobacter baumannii crab infections are a serious. Electronic publications 86507 freely accessible full text publications plus those not yet available due to embargo. Against other mdr gramnegative bacteria, however, several studies have shown higher efficacy and lower levels of resistance for combination treatment compared to monotherapy. This item appears in the following collections faculty of medical sciences 73782. Research article tigecycline therapy for nosocomial.
Combination antibiotic therapy for invasive infections with gram negative bacteria is. Emergency combination of four drugs for bloodstream. Doublecarbapenem therapy in the treatment of multidrug resistant. The resistance carbapenemresistant gramnegative bacteria in our study. Antibioticresistance percent organisms, imipenemresistant sievert d et al. The study is being conducted in 6 centres in 3 countries italy, greece and. Paul m, carmeli y, durantemangoni e, et al combination therapy for carbapenemresistant gramnegative bacteria. This study assessed, the efficacy of combination therapy against carbapenem resistant enterobacteriaceae harboring singly various extended spectrum beta lactamase or carbapenemase encoding genes. The results of the stud y can help directing and prior itising future research on the most promising therapy against carbapenemresistant bacteria. Combination therapy was the preferred treatment strategy for infections caused by carbapenemresistant gramnegative bacteria among hospital representatives. Infections caused by carbapenemresistant, gramnegative bacteria are an increasing clinical challenge, since the antimicrobial treatment options are often limited to colistin methanesulfonate. Who recognises carbapenemresistant acinetobacter baumannii, pseudomonas aeruginosa, and enterobacteriaceae as pathogens of crucial importance for the development of novel antibiotics.
Optimizing therapy in carbapenemresistant infections. Apr 01, 2021 combination therapy may be more beneficial than monotherapy in the treatment of carbapenemresistant gramnegative bacteria. This metaanalysis compared the efficacy of ceftazidimeavibactam as monotherapy or combination therapy against infections due to carbapenemresistant enterobacteriaceae cre and carbapenemresistant pseudomonas aeruginosa crpa. Most resistant to carbapenems gramnegative bacteria isolates are only susceptible to polymyxins, which are commonly the main antibiotic class used against these isolates. Epidemiology and outcome of infections with carbapenem. The patients who received tigecycline were less ill, evidenced. Apr 30, 2019 backgroundcarbapenemresistant gramnegative bacteria are a major clinical concern as they cause virtually untreatable infections since carbapenems are among the lastresort antimicrobial agents. Only randomized controlled trials rcts evaluating colistin alone and colistinbased combination therapy in the treatment of carbapenemresistant gnb infections were included.
Addon therapy with ertapenem in infections with multidrug. In vivo studies on antibiotic combination for the treatment of carbapenem resistant gram negative bacteria. Multicentre openlabel randomised controlled trial to. Pdf combination therapy for carbapenemresistant gram. Excluded versus included patients in a randomized controlled.
Out of nine in total, 2489 isolates carried resistant genes blandm1 and escherichia coli isolates carrying ndm, only four ec8, blaoxa48like. The treatment of infections caused by carbapenemresistant gramnegative bacteria crgnb has posed a major challenge to clinicians worldwide. Does the aida trial close the door on combination therapy for the treatment of all carbapenemresistant a baumannii or other gramnegative bacteria. The intrapleural colistin therapy should be considered in selected cases of pleurisy caused by multiresistant gramnegative bacteria. Treatment options for carbapenemresistant gramnegative. However, data from prospective studies about in vivo efficacy and sideeffects of colistin therapy are limited reference zavascki 8. Synergistic effects of combination therapy with a polymyxin, carbapenem, and rifampin have been observed in in vitro studies. However, an effective treatment regimen is still controversial and inadequate due to the rapid deterioration caused by the bacteria. Dec 18, 2019 evaluating a novel individualised treatment strategy for carbapenemresistant gramnegative bacteria infections the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Assessment of combination therapy in balbc mice injected. Despite the increasing use of colistin in clinical practice, the optimal dosing, and administration route have not been established. Resistance to carbapenem among gramnegative bacteria in general i. Carbapenemresistant gramnegative bacteria crgnb represent an increasing hazard in healthcare settings. Therapy for carbapenemresistant gramnegative bacteria.
Pdf intrapleural colistin methanesulfonate therapy for. Request pdf combination therapy for carbapenem resistant gram negative bacteria the emergence of resistant to carbapenems. Lactamases implicated in carbapenem resistance include kpc, ndm, and oxatype carbapenemases. Carbapenem resistance cr refers to the ability of bacteria to survive and grow in.
In vivo studies on antibiotic combination for the treatment of. Thus, four isolates harboring either bla ctxm15, bla ctxm15 and bla oxa48, bla ndm1, or bla kpc2 genes were selected for testing. In this prospective study our aim was to evaluate the efficacy of colistin and the combination of colistin and rifampicin for treatment of patients with vap due to carbapenemresistant a. Combination therapy was the preferred treatment strategy for infections caused by carbapenemresistant gramnegative bacteria among hospital representatives, even though highquality evidence for carbapenembased combination therapy is lacking. Synergistic effects of combination therapy with polymyxin, a carbapenem and rifampin pcr are observed in invitro studies. We include patients with hospitalassociated and ventilator. Active transport of carbapenem drugs out of the cell, augmented drug efflux, has been observed in some resistant species. Case reporta 92year old male resident in a nursing home was admitted to our tertiary care center in riyadh, saudi arabia, with a general deterioration. Combination therapy has garnered great interest recently, with the goals of ensuring appropriate therapy with at least one active agent, and achieving synergistic activity among the antimicrobials used. Evidence to improve the treatment of infections caused by. Objective there is poor evidence to determine the superiority of combination regimens versus monotherapy against infections due to carbapenemresistant cr gramnegative bacteria.
With less effective monotherapy and increasing resistance, evidence of retrospective studies on combination therapy of gramnegative bacterial. Multicentre openlabel randomised controlled trial to compare. Clinical data are limited to retrospective studies. Methods and analysis this is a multicentre, investigatorinitiated, openlabel, randomised controlled superiority 1. The complexities of gramnegative carbapenem resistance. In vitro models showing synergism between polymyxins and carbapenems support combination treatment for carbapenemresistant gramnegative crgn infections. Drug therapy, combination gramnegative bacteria drug effects. Colistinbased combination therapy cct is extensively used to treat infections due to carbapenemresistant gramnegative bacteria crgnb. Several observational studies have examined whether combination therapy offers an advantage over colistinpolymyxin monotherapy. In vivo studies on antibiotic combination for the treatment of carbapenemresistant gramnegative bacteria. Evaluation of risk factors and outcome of infections with. Colistin plus meropenem for carbapenemresistant gram. Colistin and tigecycline have been used as firstline agents for the treatment of infections caused by these pathogens.
The emergence of resistant to carbapenems gramnegative bacteria cr gnb has severely challenged antimicrobial therapy. While a number of novel antibiotics, such as ceftazidimeavibactam and ceftolozanetazobactam, have recently been added to the pool of existing antibiotics against crgnb, most of these agents are effective only against a subset of cr. Carbapenemresistant gramnegative bacteria also are highly transmissible and associated with outbreaks in health care settings that have significant financial ramifications. Monotherapy versus combination therapy for multidrugresistant. Combination therapy for carbapenemresistant gramnegative bacteria. Dec 01, 2019 however, no data are available in the literature regarding the superiority of ceftazidimeavibactam in combination therapy over monotherapy for the treatment of carbapenemresistant gramnegative bacteria. Combination therapy for treatment of infections with gram negative bacteria. Intravenous colistin monotherapy versus combination therapy. Combination therapy may be more beneficial than monotherapy in the treatment of carbapenemresistant gramnegative bacteria. Antimicrobial combination therapy is the current treatment approach against carbapenem resistance in. Infections due to carbapenem resistant gram negative bacteria s crgnb are ubiquitous and are associated with an overall poor outcome. Optimal therapy for infections with carbapenem resistant gramnegative bacteria is a serious problem in pediatric patients.
Combination therapy antibiotic options for pseudomonas due to mechanism of resistance. We developed an in vitro atp bioluminescence assay to determine effective antibiotic combinations against crgnb within 6 h. Is combination therapy for carbapenemresistant klebsiella. Potential advantages of combination therapy include improved efficacy due to synergy, while the disadvantages include adverse events and increased antibiotic use with a potential drive towards resistance. A central question concerning the treatment of invasive infections caused by crgnb involves the use of combination therapy.
We include patients with hospitalassociated and ventilatorassociated pneumonia, bloodstream infections and urosepsis. Exploring the use of antimicrobial combination therapy. Treatment of carbapenemresistant gramnegative bacteria. Only randomized controlled trials rcts evaluating colistin alone and colistinbased combination therapy in the treatment of carbapenemresistant. Monotherapy versus combination therapy against carbapenem. A retrospective case study xiaomaiwu, 1 yefeizhu, 1 qiuyingchen, 2 liuyanggong, 1 jianlin, 1 dongqinglv, 1 andjiaxifeng 1. Jun 11, 2020 background to compare the efficacy and safety of doublecarbapenem therapy dct with other antibiotics for the treatment of multidrug resistant mdr gramnegative bacterial infections. There are no data available from india on the usefulness of combination therapy, especially in the oncology setup. To guide the timely selection of antibiotic combinations against carbapenemresistant gramnegative bacteria crgnb, an in vitro test with a short turnaround time is essential. Adaptive trials of new antimicrobials for infections with. Impact of different antibiotic regimens in the treatment.
Doublecarbapenem therapy in the treatment of multidrug. Therefore, we performed a comprehensive and updated metaanalysis of these. Pdf the distribution of carbapenemand colistinresistance. New antibiotics and antimicrobial combination therapy for. Broad spectrum of activityin the age of increasingly resistant gram negative. Combination therapy, defined as the association of two or more antibiotics, is frequently used in clinical practice to treat cr a. We tested the association between the presence of in vitro synergism and clinical outcomes in patients treated with colistin plus meropenem. Potential advantages of combination therapy include improved. Open access protocol in vivo studies on antibiotic. Rapid antibiotic combination testing for carbapenem.
Carbapenemresistant enterobacteriaceae cre serious esblproducing enterobacteriaceae multidrugresistant acinetobacter multidrugresistant pseudomonas aeruginosa includes escherichia coli, klebsiella spp. Antibiotic treatment of infections caused by carbapenemresistant. Efficacy of ceftazidimeavibactam in monotherapy or. With combination therapy, the bacteria were eradicated from the cardiac. Stewardship resistance scan for feb 16, 2018 cidrap. Rapid antibiotic combination testing for carbapenemresistant. Combination therapy for gramnegative bacteria july 2012 volume 25 number 3 cmr. Inhalation with intravenous loading dose of colistin in. We agree with, and would like to further elaborate on, simone lanini and colleagues proposal to use adaptive randomised controlled trials to improve research on infections with carbapenemresistant gramnegative bacteria. Whether certain genotypes or phenotypes differ in their response to combination therapy remains a crucial question in the pharmacotherapy of. Infections caused by carbapenemaseproducing, multidrugresistant mdr, or extensively drugresistant xdr gramnegative bacteria.
With combination therapy, the bacteria were eradicated from the ca. Carbapenemresistant gramnegative bacteria of clinical relevance include the enterobacteriaceae, pseudomonas aeruginosa, acinetobacter baumannii, and more recently, stenotrophomonas maltophilia. Pubmed, embase, and cochrane databases were searched up to july 2018. The treatment of infections caused by multidrugresistant gramnegative bacteria is challenging given the limited options for effective therapy. Intravenous colistin monotherapy versus combination. The sample included 171 patients with infections caused by carbapenemresistant acinetobacter baumannii n 1, enterobacteriaceae n 37 and pseudomonas aeuruginosa n 3. In immunocompromised and neutropenic patients, mdrbsi is an emergency, which causes treatmentrelated mortality. Patients presenting with bloodstream infections caused by multidrug resistant klebsiella pneumoniae were treated with a combination treatment. Infections caused by multidrugresistant mdr gram negative bacteria gnb are. In vivo models can simulate the pathophysiology of infections in humans and assess antibiotic efficacy. Open access protocol multicentre openlabel randomised. A comparison of colistin versus colistin plus meropenem for.
Many cr gnb isolates are only susceptible to polymyxins. The study is being conducted in 6 centres in 3 countries italy, greece and israel. In patients who received any colistin plus meropenem, clinical failure at 14 days was 5978 75. What is best available therapy bat for the treatment of carbapenemresistant gram. Combination therapy for carbapenemresistant gramnegative. Frontiers infections caused by carbapenemresistant. We aim to investigate in vivo effects of antibiotic combination on mortality and disease burden for infections due to cr acinetobacter baumannii, pseudomonas aeruginosa and enterobacteriaceae and. Mar 31, 2021 we performed an investigatorinitiated, multicenter, openlabel, parallel group, randomized controlled trial aida study, which compared colistinmeropenem combination therapy to colistin monotherapy in the treatment of patients infected with carbapenemresistant gramnegative bacteria cr gnb.
Resistance to carbapenems in pseudomonas aeruginosa, acinetobacter baumannii and enterobacteriaceae, mainly determined by the production of carbapenemhydrolyzing. Carbapenemresistant gramnegative bacteria bacteriology. Colistin may work in combination with other antibiotics such as meropenam and tigecycline. Combination therapy for treatment of infections with gram. The molecular mechanism of carbapenem resistance in a baumannii was not included in this analysis. Tigecycline therapy for nosocomial pneumonia due to carbapenemresistant gramnegative bacteria in critically ill patients who received inappropriate initial antibiotic treatment. Evaluating a novel individualised treatment strategy for. In vitro testing showed synergism for 73 isolates, antagonism for 20 and additivismindifference for 78. The emergence of resistant to carbapenems gram negative bacteria cr gnb has severely challenged antimicrobial therapy. Carbapenemresistant cr gramnegative bacteria gnb are gaining increasing importance in healthcare settings, especially in highdependency units and among critically ill patients. All types of studies were included if they had evaluated.
Antibiotic treatment of infections caused by carbapenem. Infections with carbapenemresistant gramnegative bacteria crgnb are increasing and are associated with a high mortality. Several studies showed that carbapenem combination therapy has lower mortality rates than other combinations8,9. Bloodstream infection bsi caused by multidrugresistant mdr bacteria or extensively drugresistant xdr bacteria is a global threat. In vivo studies on antibiotic combination for the treatment. In acinetobacter baumannii infections carbapenemnonsusceptible gramnegative bacteria, colistin plus meropenam. Potential advantages of combination therapy include improved efficacy due to synergy. Infections caused by multidrugresistant mdr gramnegative bacteria gnb are. No data are available regarding the pharmacokinetics of colistin in pleural fluid. An online literature search was conducted to identify observational studies published as full papers and indexed. We tested 42 clinical crgnb strains 14 acinetobacter baumannii, 14 pseudomonas aeruginosa. Optimal therapy for infections with carbapenem resistant gnb is not well established due to the weakness of data. Combination antibiotic therapy for invasive infections with gramnegative bacteria is.
Request pdf combination therapy for carbapenemresistant gramnegative bacteria the emergence of resistant to carbapenems gramnegative bacteria cr gnb has severely challenged antimicrobial. Colistin use was associated with increased survival rates if administered as part of combination regimens with tigecycline, an aminoglycoside, or meropenem particularly. Feb 16, 2018 trial finds no benefit of combo drugs for severe carbapenemresistant infections. Jan 15, 2020 the carbapenemresistant gramnegative bacteria are a group of bacteria that have developed resistance against carbapenem antibiotics a last resort drug of administration for most gramnegative bacterial infections that have developed resistance against all possible antibiotics.
448 1445 594 1405 491 1240 39 1293 1047 1140 160 1080 231 184 918 1478 105 547 1117 85 1131 1039 516 645 869 1351 927